کد مقاله کد نشریه سال انتشار مقاله انگلیسی نسخه تمام متن
5882744 1149597 2013 5 صفحه PDF دانلود رایگان
عنوان انگلیسی مقاله ISI
Original studyPatients Treated With Platinum-Doublet Chemotherapy for Advanced Non-Small-Cell Lung Cancer Have Inferior Outcomes If Previously Treated With Platinum-based Chemoradiation
ترجمه فارسی عنوان
مطالعه اصلی پزشکان با استفاده از شیمیدرمانی پلاتین-دوتت برای سرطان پیشرفته سلولهای غیر سلولی کوچک پیشرفته تر از قبل درمان شده با شیمی درمانی پلاتین
کلمات کلیدی
موضوعات مرتبط
علوم پزشکی و سلامت پزشکی و دندانپزشکی بیهوشی و پزشکی درد
چکیده انگلیسی

IntroductionThe standard of care for locoregionally advanced non-small-cell lung cancer is concurrent platinum-based chemoradiation. Many patients relapse, and subsequent systemic treatment may involve platinum-doublet chemotherapy. It is not known if prior platinum-based chemoradiation influences the response to platinum-based chemotherapy given subsequently for relapse. Therefore, we compared outcomes in these patients with those in patients without prior treatment.MethodsA retrospective study of patients who had been treated with carboplatin and gemcitabine chemotherapy for de novo metastatic disease or recurrent non-small-cell lung cancer after receiving platinum-based chemoradiation. The primary outcome was progression-free survival (PFS).ResultsA total of 104 patients were analyzed. The median age was 63 years (range, 35-81 years), with 63 (61%) patients with newly diagnosed disease and with 41 (39%) who were previously treated. The response rate was significantly lower for those previously exposed to chemoradiation (10% vs. 29%: P = .001), as was the median PFS (3.6 months vs. 5.7 months; P = .002), and median overall survival (OS) (8.6 months vs. 12.1 months; P = .007). Only the treatment group was a significant predictor (P = .032) of PFS by univariate analysis. In univariate analysis; sex (men; P = .04), histology (squamous cell; P = .04), Eastern Cooperative Oncology Group Performance Status Scale (P = .002), and treatment group (P = .023) predicted significantly inferior OS. Multivariate analysis showed that performance status was the only significant predictor of inferior OS.ConclusionOutcomes were inferior in patients previously exposed to platinum-based chemoradiation. An approach of stratifying such patients in future trials of chemotherapy should be adopted. Alternative options such as non-platinum-based agents or targeted therapies should be considered in this group.

ناشر
Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: Clinical Lung Cancer - Volume 14, Issue 5, September 2013, Pages 508-512
نویسندگان
, , , , , , , ,